Literature DB >> 29951914

The co-occurrence of driver mutations in chronic myeloproliferative neoplasms.

Prajwal Boddu1, Dai Chihara2, Lucia Masarova1, Naveen Pemmaraju1, Keyur P Patel3, Srdan Verstovsek4.   

Abstract

Myeloproliferative neoplasms (MPNs) are clonal disorders characterized by proliferation of one or more elements of the myeloid lineage. Key genetic aberrations include the BCR-ABL1 gene rearrangement in Philadelphia chromosome-positive chronic myelogenous leukemia (CML) and JAK2/MPL/CALR aberrations in Philadelphia chromosome-negative MPNs. While thought to be mutually exclusive, occasional isolated reports of coexistence of BCR-ABL1 and JAK2, and JAK2 with MPL or CALR aberrations have been described. Given the paucity of data, clinical characteristics and outcome of patients harboring concurrent Philadelphia-positive and Philadelphia-negative mutations or dual Philadelphia-negative driver mutations have not been systematically evaluated, and their clinical relevance is largely unknown. It is difficult to determine the true relevance of co-existing driver mutations on outcomes given the rarity of its occurrence. In this case series, we describe those patients who had dual driver mutations detected at any point during the course of their disease and characterized their clinical and laboratory features, bone marrow pathology, and overall disease course.

Entities:  

Keywords:  CALR; Chronic myeloid leukemia; JAK2; MPL; Myeloproliferative neoplasm; Philadelphia

Mesh:

Substances:

Year:  2018        PMID: 29951914     DOI: 10.1007/s00277-018-3402-x

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  10 in total

1.  Double-mutant myeloproliferative neoplasms.

Authors:  Stephen E Langabeer
Journal:  Med Oncol       Date:  2018-08-29       Impact factor: 3.064

Review 2.  Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.

Authors:  Ruochen Jia; Robert Kralovics
Journal:  Int J Hematol       Date:  2019-11-18       Impact factor: 2.490

3.  Analysis of human mitochondrial genome co-occurrence networks of Asian population at varying altitudes.

Authors:  Rahul K Verma; Alena Kalyakulina; Cristina Giuliani; Pramod Shinde; Ajay Deep Kachhvah; Mikhail Ivanchenko; Sarika Jalan
Journal:  Sci Rep       Date:  2021-01-08       Impact factor: 4.379

Review 4.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

Review 5.  Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.

Authors:  Yanhua Yue; Wei Wei; Yanting Guo; Fei Wang; Weimin Dong; Yue Liu; Yan Lin; Yang Cao; Weiying Gu
Journal:  Am J Case Rep       Date:  2020-10-06

6.  Emergence of BCR-ABL1 Chronic Myeloid Leukemia in a JAK2-V617F Polycythemia Vera.

Authors:  Mariana Lorenzo; Sofia Grille; Mariana Stevenazzi
Journal:  J Hematol       Date:  2020-04-23

Review 7.  Atypical myeloproliferative neoplasm with concurrent BCR-ABL1 fusion and CALR mutation: A case report and literature review.

Authors:  Chunshui Liu; Ruiping Hu; Zhonghua Du; Manuel Abecasis; Cong Wang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

8.  Concurrent chronic myeloid leukemia and CALR-mutated myeloproliferative neoplasm.

Authors:  Stephen E Langabeer
Journal:  EXCLI J       Date:  2020-01-08       Impact factor: 4.068

9.  Primary myelofibrosis with concurrent CALR and MPL mutations: A case report.

Authors:  Feng-Ping Zhou; Cheng-Cheng Wang; Hua-Ping Du; Shan-Bo Cao; Jin Zhang
Journal:  World J Clin Cases       Date:  2020-11-26       Impact factor: 1.337

10.  A Rare Co-Occurrence of Triple Mutations in JAK2, CALR, and MPL in the Same Patient with Myelofibrosis.

Authors:  Sherine J Thomas; D P Dash
Journal:  Case Rep Hematol       Date:  2022-02-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.